Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · SHUKRA PHARMACEUTICALS L · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
SHUKRA PHARMACEUTICALS L NSE: SHUKRAPHAR · BSE: 524632
SHUKRA PHARMACEUTICALS L is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
₹ crore · consolidated
FY26
Revenue
57
EBITDA (ex other income)
29
margin %
50.7
Owners' profit
22
EPS, as reported (₹)
0.50
ROE % · ROCE %
24.6 · 31.7
Debt / equity (x)
0.06
Cash from operations
4
Capex
0
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SHUKRA PHARMACEUTICALS L · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 2 quarters
₹ crore
Q3 FY26
Q4 FY26
Revenue
39
6
Profit before tax
27
0
Net profit
20
(2)
EPS (₹)
0.47
0.04
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
SUN PHARMACEUTICAL IND L
4,22,229
34.9
5.03
22.6
13.7
17.5
11.8
32.3
DIVI S LABORATORIES LTD
2,48,067
84.9
14.80
64.0
15.3
18.8
8.7
42.8
TORRENT PHARMACEUTICALS L
1,56,270
73.8
8.89
38.8
12.2
8.0
11.8
33.1
ZYDUS LIFESCIENCES LTD
1,10,978
24.8
3.75
14.4
17.3
18.0
12.4
25.2
LAURUS LABS LIMITED
1,07,937
98.6
19.87
60.1
16.4
17.2
7.2
32.0
CIPLA LTD
1,05,570
31.3
3.06
16.1
11.2
14.7
8.0
19.7
DR. REDDY S LABORATORIES
98,530
30.5
2.58
13.2
10.9
13.0
12.1
15.0
MANKIND PHARMA LIMITED
98,294
48.1
5.94
27.1
11.7
10.8
—
27.3
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
131.3
31.2
148 of 158
6%
P/B
32.6
3.1
163 of 163
0%
ROCE
30.5
10.8
9 of 183
96%
ROE
24.6
9.8
12 of 166
93%
Debt / Equity
0.1
0.2
69 of 166
59%
EBITDA margin
26.1
17.5
48 of 165
71%
Market cap
2933
857
69 of 181
62%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SHUKRA PHARMACEUTICALS L · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
6 Oct 2026 · Company says no undisclosed info behind recent price movement
regulatory legal
low
—
—
6 Oct 2026 · BSE seeks clarification on significant price movement
regulatory legal
high
—
—
29 Sept 2026 · Postal Ballot Results: Name Change to Shukra Medtech Approved
board shareholder meetings
low
—
—
29 Sept 2026 · Shukra Pharma 33rd AGM: All 4 Resolutions Passed, Final Dividend Approved
board shareholder meetings
low
—
—
28 Sept 2026 · Shukra Pharma 33rd AGM: Dividend Approved, New Director Appointed
board shareholder meetings
low
—
—
24 Sept 2026 · Trading window closed for insiders from Oct 1 till Q2 FY27 results
compliance
minimal
—
—
23 Sept 2026 · Newspaper publication of corrigendum to postal ballot notice
compliance
minimal
—
—
22 Sept 2026 · Corrigendum to Postal Ballot Notice for Name Change to Shukra Medtech
board shareholder meetings
low
—
—
18 Sept 2026 · Shukra Pharmaceuticals fixes Sep 21, 2026 as record date for final dividend
corporate actions
medium
—
—
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
